Asset
Ordastobart
Inhibrx Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06295731 | phase2_3 | active_not_recruiting | 2024-05-14 | 2029-05-01 | Inhibrx Biosciences, Inc | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC |
FDA applications (0)
This company has no applications containing this asset.